INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is a common, genetically complex disease caused, and accelerated in its progression, predominantly by tobacco smoking. High smoking intensity, likely related at least in part to nicotine addiction, increases the risk of developing COPD. Although many patients quit smoking after they are diagnosed with COPD, some continue to smoke, placing them at high risk for continued disease progression.
Smoking behaviors, such as age at smoking initiation, smoking cessation, and number of cigarettes smoked per day (CPD), are partially genetically determined and have substantial heritability. [1] [2] [3] [4] Numerous loci and candidate genes have been suggested to contain genetic markers affecting smoking behaviors using genome-wide linkage scans 5 and genome wide association study approaches. 67 Recent Genome Wide Association Studies (GWAS) have identified loci associated with smoking cessation (Dopamine Beta-Hydroxylase on chromosome 9q34) and CPD (e.g. nicotinic acetylcholine receptor locus on chromosome 15q25 and Cytochrome P2A6 (CYP2A6) locus on chromosome 19q13) in multiple populations, [8] [9] [10] [11] although GWAS of smoking behaviors specifically within COPD subjects have not been reported. Interestingly, the same single nucleotide polymorphisms (SNPs) in the 15q25 locus were previously associated with development of COPD, 12 but the role of this locus in smoking behaviors in COPD patients and whether the sole effect of this locus on COPD susceptibility relates to smoking behavior remain unclear.
Due to their typically heavy lifetime smoking exposures, potentially related to (at least in part) enrichment in genetic variants responsible for nicotine addiction, COPD subjects can be considered as a unique population for studying smoking behaviors. However, diagnosis and further progression of COPD are likely to modify smoking status (i.e. increased efforts to quit smoking) and smoking intensity (e.g. reduction of CPD). Identifying genetic factors involved in smoking cessation is of special importance in clinical practice, since quitting smoking may reduce subsequent loss of lung function in COPD patients. 1314 Smoking cessation results in an improvement of respiratory symptoms in COPD patients, and is associated with reduced mortality due to COPD. [13] [14] [15] [16] Another smoking-related phenotype, age at smoking onset, correlates with nicotine dependence in adulthood 17 and mortality due to COPD. 15 Taken together, it is of special interest to search for markers associated with smoking behaviors uniquely among COPD patients. Likewise, it is of importance to assess whether SNPs, regarded as established genetic determinants of smoking cessation and CPD in other populations, associate with these traits in COPD patients as well. Identification and description of such genetic variations may have significant consequences on future, targeted therapy aiming to reduce smoking among COPD patients.
The aim of the current study was to identify SNPs associated with age at smoking initiation, smoking cessation, current and lifetime average CPD among COPD subjects, using GWAS in four independent cohorts: National Emphysema Treatment Trial (NETT), Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE), GenKOLS cohort from Bergen, Norway, and COPDGene. We hypothesized that a subset of smoking behavior genetic determinants in other population samples would influence smoking behavior in COPD subjects.
METHODS

Subjects and phenotypes
Ever-smoking, Caucasian subjects with at least moderate COPD (GOLD stage II or higher) from four independent cohorts (NETT, 18 ECLIPSE, 19 GenKOLS cohort from Bergen, Norway, 20 and COPDGene (first 1000 subjects) 21 ) were studied (Table 1 ). In total 3,441 subjects had at least 1 (out of 4) non-missing, smoking-related phenotype (Table 1) . All phenotypes were self-reported using either Case Report Form (smoking status and the lifetime average CPD in the ECLIPSE cohort) or modified versions of the American Thoracic Society/Division of Lung Diseases Respiratory Disease Questionnaire. 22 Since current smokers were not eligible for the NETT study, this cohort did not contribute to the analyses on smoking cessation and current CPD.
Genotyping and quality control (QC)
Different genotyping chips from Illumina (Illumina Inc., San Diego, CA) were used (table  1) . QC steps were previously described in detail for the NETT, Norwegian and ECLIPSE cohorts, 23 and were applied to the COPDGene study as well. Briefly, QC steps consisted of filtering SNPs based on missing call rates (>5%) and Hardy-Weinberg Equilibrium deviation (p<10 −8 ), and filtering subjects based on genotyping call rate (<95%), sex discrepancy, unexpected relatedness (PLINK pi-hat cutoff of 0.125), and ethnicity. Removal of cases that were outliers for genetic ancestry was performed based on principal components (PCs) analysis in cases only. In the primary analysis, untyped markers were imputed using 120 founder Caucasian (Centre d'Etude du Polymorphisme Humain (Utah residents with ancestry from northern and western Europe) (CEU)) haplotypes from HapMap reference panel (phase II) and, as a secondary analysis, using 1000 Genomes Project data. 2425 We limited our analysis to SNPs genotyped/imputed in at least 2 cohorts, with imputation r 2 coefficient ≥0.3 (for imputed SNPs only). Overall, approximately 2.5 and 6.3 million SNPs per phenotype were analyzed using the reference HapMap Project and 1000 Genomes Project panels, respectively.
Association analysis of candidate SNPs
We extracted candidate SNPs achieving genome-wide significance in the previous studies on smoking cessation and CPD. Following previous GWAS, 89 we additionally extracted two SNPs from CYP2A6 (rs1801272 (Leu160His)) and CHRNA5 (rs588765) based on their biological function. Since a candidate SNP from the DBH locus and most of the candidate SNPs from the CYP2A6 locus were imputed in all cohorts, we searched for the best proxy SNP genotyped in at least 3 of the cohorts.
Statistics
According to Box-Cox transformation 27 that identified approximately the best transformation of dependent variables, which could be applied to all cohorts, we studied log 2 -transformed age at smoking initiation and lifetime average CPD, and the square root of the current CPD. Regression models were run under an additive model coded SNPs, while adjusting for potential confounders (see online supplementary material for details). A fixed effect model was used for all meta-analyses. Effect allele was defined as the one associated with later age at smoking initiation, higher CPD or higher odds for smoking cessation. Metaanalytic p<5×10 −8 was considered as genome-wide significant; 28 5×10 −8 ≤p<5×10 −7 was interpreted as a suggestive association in the genome-wide panel with p<0.05 a suggestive association for candidate SNPs.
Software
Box-Cox transformations were performed with MASS package 27 , while lambda inflation factors were calculated with GenABEL package 29 in R (ver. 2.10.1). 30 SNP imputation was performed with MACH (ver. 1.0). 31 PCs, reflecting genetic structure of each study population, were calculated and analyzed with the EIGENSOFT package (ver. 2.0). 32 Genetic association analyses and meta-analyses were run with PLINK (ver. 1.0.7). 3334 SNAP (ver. 2.2) 35 was used to search for proxy SNPs (r 2 ≥0.8) using the Caucasian HapMap phase II panel and to assess linkage disequilibrium (LD) coefficients in 1000 Genomes Project data. SNP/gene annotations and regional association plots were created with LocusZoom (ver. 1.1; human genome build hg18). 36 
RESULTS
Age at smoking initiation
Analyses in the individual cohorts were adjusted for sex and principal components for genetic ancestry. In total, meta-analysis included 3,397 subjects for the age at smoking initiation phenotype. Lambda inflation factors were between 0.986 and 1.019 for individual cohorts (table 1), and 1.002 for meta-analytic p values (see online supplementary figure 1 for a Q-Q plot of meta-analysis). No SNPs showed meta-analytic association p values below the genome-wide significance level. Numerous SNPs in the intergenic region on chromosome 2q21 and in the region between BCL2-antagonist/killer 1 (BAK1) and Zinc finger and BTB domain containing 9 (ZBTB9) on chromosome 6p21 were associated with age at smoking initiation at a suggestive significance level (figure 1 and online supplementary table 1). In total 24 SNPs were associated with age at smoking initiation with p<10 −5 in the meta-analysis (online supplementary table 1).
Lifetime average CPD
Analyses in single cohorts were adjusted for sex, age and principal components for genetic ancestry. In total, meta-analysis included 3,440 subjects for the lifetime average CPD phenotype. Lambda inflation factors were between 0.996 and 1.018 for individual cohorts (table 1), and 1.019 for meta-analytic p values (see online supplementary figure 2 for a Q-Q plot of meta-analysis). Thirteen SNPs were associated with lifetime average CPD with metaanalytic p<10 −5 , however, no SNPs showed association with meta-analytic p<10 −6 (table 2).
Candidate SNPs from the nicotinic acetylcholine receptor locus on chromosome 15q25 (rs578776, rs588765, rs8034191, rs1051730 and rs16969968) were significantly (p<0.05) associated with lifetime average CPD with the same direction of effect as seen in previous GWAS on CPD (table 2). The synonymous rs1051730 SNP was the top associated SNP in this locus (figure 2).
Four candidate SNPs (rs7251570, rs4105144, rs1801272 and rs12461383) in the CYP2A6 locus on chromosome 19q13 were significantly (p<0.05) associated with lifetime average CPD with the same direction of effect as seen in previous GWAS on CPD (table 2) . A nonsynonymous SNP (rs1801272) was the second most significantly associated SNP in this locus (figure 2, table 2 ). There is, at most, a moderate level of LD between these 4 SNPs according to the HapMap phase II panel (r 2 ≤0.6 and D'≥0.84, see online supplementary figure 3). Analysis of proxy SNPs that were genotyped in at least three cohorts was performed. Analysis of rs8102683 (genotyped in the NETT, ECLIPSE and Norwegian cohorts, and imputed in COPDGene) that is a proxy for rs4105144 (r 2 =0.87), and rs7251418 (genotyped in all cohorts) that is a proxy for rs7251570 (r 2 =0.81) confirmed the associations observed (p= 4.65×10 −5 (B=0.074 for the "C" effect allele; I 2 =0) and p=0.0024 (B=0.054 for the "G" effect allele; I 2 =0), respectively). No genotyped proxy SNPs could be found for rs12461383 and rs1801272 SNPs. We did not replicate, with a nominal p<0.05, associations between SNPs in 7p14, 8p11 and 10q23 loci, reported in previous GWAS on CPD in our analysis on lifetime average CPD (online supplementary table 2).
Smoking cessation
Analyses in single cohorts were adjusted for age, % of predicted FEV 1 and principal components summarizing genetic ancestry. In total, meta-analysis included 1,164 current smokers (defined as "No" for smoking cessation) and 1,907 former smokers (defined as "Yes" for smoking cessation). Lambda inflation factors were between 0.995 and 1.000 for individual cohorts (table 1), and 0.998 for meta-analytic p values (see online supplementary figure 4 for a Q-Q plot of meta-analysis). No SNPs showed association with meta-analytic p<10 −6 (table 3) . Candidate SNP rs3025343 in the DBH locus showed nominally significant association with smoking cessation with the same direction of effect as seen in recent GWAS, yet with substantial heterogeneity between studies (table 3) . SNP rs3025316, a proxy for rs3025343 (r 2 =0.94), was genotyped in all cohorts and confirmed this association (p= 0.002 (OR= 1.32 for the "T" effect allele; I 2 =18).
Current CPD
Analyses were adjusted for sex, age, % of predicted FEV 1 , and principal components for genetic ancestry. In total, meta-analysis included 1,113 current smokers for the current CPD phenotype. Lambda inflation factors were between 0.995 and 1.005 for individual cohorts (table 1), and 1.010 for meta-analytic p values (see online supplementary figure 5 for a Q-Q plot of meta-analysis). No SNPs showed meta-analytic association with p<10 −6 (table 4) . Among candidate SNPs, rs12461383 from the CYP2A6 locus was significantly associated with current CPD with the same effect direction as compared to previous GWAS on CPD (table 4) . Candidate SNPs rs1801272 and rs7251570 showed borderline significant association with the same effect direction as compared to previous GWAS on CPD (table 4) . We did not replicate, at a nominal p< 0.05, associations between SNPs in 7p14, 8p11 and 10q23 loci reported in previous GWAS on CPD in our analysis on current CPD (online supplementary table 3).
Analyses of SNPs Imputed with 1000 Genomes Project Data
Analysis of all phenotypes using SNP genotypes imputed using the 1000 Genomes Project revealed 20 additional associations below the suggestive genome-wide significance level (supplementary table 4 ). SNP rs9394152 in the 6p21 locus was the most significantly associated SNP with the age at smoking initiation (meta-analytic p=6.55×10 −8 ) and, similarly to the majority of SNPs associated with this phenotype below suggestive genomewide significance level, was characterized by high (≥0.96), cohort-specific imputation r 2 coefficients (supplementary table 4 ). We observed novel associations of 3 SNPs with the lifetime average CPD; the most significantly associated SNP rs28675338 (r 2 =0.07 and D'=1.00 to rs1051730 according to 1000 Genomes Project Data) maps to the 15q25 locus. We also found one SNP associated with smoking cessation, with meta-analytic p<5×10 −7 (supplementary table 4 ). Since cohort-specific, imputation r 2 coefficients of the 4 SNPs, associated with lifetime average CPD and smoking cessation below suggestive genomewide significance level, were rather modest (range 0.35-0.64; supplementary table 4), the observed associations certainly require additional confirmation and should be interpreted with caution. The three SNPs associated with current CPD with meta-analytic p<5×10 −7 map to regions on chromosomes 2 and 3 (supplementary table 4), which were already ranked as top loci using the HapMap II reference panel (table 4) .
DISCUSSION
Cigarette smoking is the most important environmental risk factor for COPD, and smoking cessation is the most important therapeutic intervention to prevent its progression. Our current study identified two loci on chromosomes 2q21 and 6p21 as candidates for containing genes influencing age at smoking initiation in COPD patients, both showing suggestive levels of genome-wide significance. Furthermore, this study confirmed that certain SNPs in the nicotinic acetylcholine receptor locus on chromosome 15q25 and SNPs in the CYP2A6 locus on chromosome 19q13 were associated with CPD in COPD patients. Of importance, we additionally confirmed in COPD subjects the previously reported association of a marker (rs3025343) in the DBH locus with smoking cessation.
The two loci mapping to chromosomes 2q21and 6p21showed evidence of association with age at smoking initiation at a suggestive genome-wide significance level, using both HapMap II and 1000 Genomes projects reference imputation panels. The association peaks found here do not localize within any known genes, suggesting distant regulation of yet unidentified target genes may be involved. SNPs from chromosome 6p21 are located close to the Human Leukocyte Antigen locus, and ZBTB9 and BAK1 are the closest genes to the association peak. The BAK1 gene, encoding a proapoptotic protein, has been previously associated by GWAS with testicular germ cell tumors 37 and platelet number. 38 Yet SNPs identified in these studies do not correlate, in terms of LD, with top SNPs from our age at smoking initiation GWAS.
Analysis of candidate SNPs, with respect to the lifetime average CPD, revealed that the majority of those SNPs in the CHRNA3/CHRNA5 (15q25) and CYP2A6 (19q13) regions significantly associated with this trait showed the same direction of effect described previously. However, SNPs from the 7p14, 8p11 (CHRNB3/CHRNA6 locus) and 10q23, as well as some SNPs from the CYP2A6 and CHRNA3/CHRNA5 loci, were not replicated in the current study with a nominal significance threshold. This may be caused by effect sizes that are too small to be detected in our populations or potentially to different genetic determinants of smoking behaviors within COPD subjects.
Besides the "neutral" or reference haplotype, it has been suggested there are at least 2 other haplotypes with independent effects on CPD in this 15q25 region. 2639 Our study confirms previous observations that rs1051730, and tagging SNPs such as rs16969968, exhibit relatively strong effects in this region, and SNPs rs588765 and rs578776, determine independent haplotypes associated with lifetime CPD in COPD patients as well. However, we could not replicate association between lifetime average CPD and rs684513, i.e. the top SNP in the analysis on CPD when conditioning for rs1051730 in the Tobacco and Genetics Consortium. 10 Importantly, the effect directions of all candidate SNPs in this 15q25 locus agree with those previously reported, suggesting larger COPD cohorts are required to establish significance of independent SNPs/haplotypes in this region.
Interestingly, effect sizes of replicated SNPs from the CHRNA3/CHRNA5 locus are similar to most of those from the CYP2A6 locus in our study, which contrasts with recent GWAS where bigger effect sizes were seen for the former locus. 8 Additionally, variations in the CHRNA3/CHRNA5, but not CYP2A6, locus showed substantial heterogeneity in genetic effects in our study, and as observed in previous GWAS as well. 810 We speculate that this might be due to between-study differences in general (e.g. educational status or peer smoking 40 ) or COPD-specific (e.g. reporting lifetime average CPD which may be influenced by severity of disease) characteristics.
Analysis of current CPD, which was much less powered than lifetime CPD due to a lower number of subjects, was still able to detect some evidence of association with markers near CYP2A6, yet not for those located in the CHRNA3/CHRNA5 region. CYP2A6 is an enzyme primarily responsible for conversion of nicotine to cotinine in the liver, and rs1801272 (Leu160His) codes for the CYP2A6*2 allele, which inactivates the enzyme. 41 This SNP showed the largest effect size on both current and lifetime average CPD among all analyzed candidate SNPs in the region. Leu160His is in LD (D'=1.0) with other SNPs that were replicated in the CYP2A6 locus. This agrees with previous GWAS and suggests that the rs1801272 SNP may be a true causative variant, while the other associations observed may be due to partial tagging by this SNP. 8 Importantly, we show that the genotyped proxy SNPs in the CYP2A6 locus confirmed our analysis on imputed SNPs with respect to lifetime average CPD. The lack of convincing association for the proxy SNP rs7251418 with current CPD may be explained by the relatively smaller sample size in this analysis, and incomplete LD between the target and the proxy SNPs. Previous GWAS suggested that other genes may be associated with CPD in the 19q13 region, yet we observed no nominally significant associations for EGLN2, RAB4B and CY2B6.
Analysis of smoking cessation did not reveal any loci associated below the suggestive significance level, and it showed that the previously reported 10 association between rs3025343 in the DBH locus can be replicated in COPD subjects with a nominal significance threshold. DBH is a plausible candidate gene for smoking cessation since it participates in the metabolism of dopamine. This neurotransmitter is released from neurons in response to nicotine, 3 and is an important mediator of addiction behaviors such as smoking. The rs3025343 SNP that we extracted showed a substantial heterogeneity in this effect, which may reflect the between-study differences in factors such as use of nicotine replacement therapy or socio-economic status. Interestingly, the best proxy SNP rs3025316 (genotyped in all cohorts) showed a more pronounced effect with somewhat smaller heterogeneity index compared to the rs3025343.
Our study possesses several limitations, and some of those are typical for many GWAS. For example, the size of the current study may have been too small to detect associations at a genome wide significance level. Phenotypes studied are genetically complex and are likely determined by many genes of modest effects, which makes them difficult to detect with genome-wide significance for the currently studied sample size. It is worth noting that the much larger Tobacco and Genetics Consortium did not identify any genome-wide significant associations for age at smoking initiation in a meta-analysis encompassing over 20,000 individuals. 10 This emphasizes the need for even larger studies to study smoking behaviors in order to detect variants with presumably low effect sizes. Despite the modest effect sizes of the genetic variants implicated by GWAS, key biological pathways may be identified using such approaches. Secondly, the genotype imputation accuracy could have had an impact on our results. Many top SNPs from the analyses of age at smoking initiation were imputed in all 4 cohorts; however, the association peaks of these regions also contained SNPs genotyped in the majority (or even all) of the cohorts, which likely makes these findings more reliable. Given the fact that different, and not fully overlapping, genotyping chips were used, this imputation was crucial to obtain a comprehensive overview of many genetic associations. In our study, this is of special importance for the nonsynonymous SNP rs1801272 in CYP2A6, which had to be imputed in all cohorts and has no known proxy SNPs. Assuming that the association of this SNP with CPD is a true positive and possibly causal, imputation was the only one way to detect it. Lastly, we must acknowledge that COPD diagnosis has a significant impact on smoking behaviors studied, and especially on current CPD and smoking cessation. We took into account the severity of COPD, reflected in the level of lung function, as a potential confounder when analyzing these two phenotypes. However, we hypothesize that additional factors such as frequency of exacerbations may also affect smoking behaviors in the COPD subjects that were studied here. Additionally, it is plausible that social factors, such as smoking trends changing over time, are important environmental determinants of smoking initiation and intensity, and they might have potentially confounded genetic associations found.
In summary we identified two candidate loci associated with age at smoking initiation in COPD patients. We show that variation in the CHRNA3/CHRNA5 locus on chromosome 15q25 locus and the CYP2A6 locus on chromosome 19q13 were associated with lifetime average CPD among COPD patients. The latter gene may play a significant role in the current smoking intensity among COPD patients. Future studies in larger populations of COPD subjects will be required to determine the overlap between genetic determinants of smoking behavior in the general population and in COPD subjects.
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Figure 1. Regional association plots of two loci including SNPs associated with age at smoking initiation with meta-analytic p<10 −6
Dots correspond to meta-analyzed SNPs. Color of dots corresponds to r 2 (linkage disequilibrium (LD) coefficient in the HapMap II CEU population; grey dots correspond to SNPs with missing LD information) relative to the most significantly associated SNP (depicted with diamond) in the region i.e. rs13408379 (top figure) and rs9380362 (bottom figure).
Figure 2. Regional association plots of the candidate loci centered on CHRNA3 (top) and CYP2A6 (bottom) and their associations with lifetime average number of cigarettes smoked per day
Dots correspond to meta-analyzed SNPs. Color of dots correspond to r 2 (linkage disequilibrium (LD) coefficient in the HapMap II CEU population; grey dots correspond to SNPs with missing LD information) relative to the most significantly associated SNP in the region (depicted with diamond) i.e. rs1051730 in the CHRNA3 (top figure) and rs1496402 (bottom figure; the second top SNP in this region is a nonsynonymous (Leu160His) rs1801272 SNP in the CYP2A6). CHRNA3=alpha-nicotinic acetylcholine receptor 3; CYP2A6=Cytochrome P450 2A6 SNPs associated with the lifetime average CPD (log 2 -transformed) with meta-analytic p<10 −5 , and candidate SNPs from CHRNA3/ CHRNA5 and CYP2A6 loci identified by previous studies SNPs associated with smoking cessation with meta-analytic p<10 SNPs associated with the current CPD (square-root transformed) with meta-analytic p<10 -5 , and candidate SNPs from CHRNA3/CHRNA5 and CYP2A6
loci identified by previous studies 
